Clinical Trial Update: Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating OLX10212 for neovascular age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• OLX10212

Snippet

Sponsor: Olix Pharmaceuticals, Inc. | Conditions: Neovascular Age-related Macular Degeneration | Phase 1 | Status: COMPLETED